Research programme: MYC oncoprotein modulators - AvalonAlternative Names: MYC inhibitors - Avalon
Latest Information Update: 19 Aug 2008
At a glance
- Originator Avalon Pharmaceuticals
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Aug 2008 Discontinued for Cancer in USA (unspecified route)
- 22 Feb 2007 Early research in Cancer in USA (unspecified route)